NeoGenomics Reports Revenue of the Fourth Quarter of 2017

NeoGenomics (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017.

As quoted in the press release:

Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016. After adjusting 2016 results for the divestiture of PathLogic, revenue growth was 15%. Clinical genetic test volume⁽¹⁾ increased by almost 19% year over year. Average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $338, primarily due to changes in test mix and reduced reimbursement levels for certain molecular tests.

Click here to read the full press release.